| Year |
Citation |
Score |
| 2004 |
Dance AL, Miller M, Seragaki S, Aryal P, White B, Aschenbrenner L, Hasson T. Regulation of myosin-VI targeting to endocytic compartments. Traffic (Copenhagen, Denmark). 5: 798-813. PMID 15355515 DOI: 10.1111/J.1600-0854.2004.00224.X |
0.628 |
|
| 2004 |
Swiatecka-Urban A, Boyd C, Coutermarsh B, Karlson KH, Barnaby R, Aschenbrenner L, Langford GM, Hasson T, Stanton BA. Myosin VI regulates endocytosis of the cystic fibrosis transmembrane conductance regulator. The Journal of Biological Chemistry. 279: 38025-31. PMID 15247260 DOI: 10.1074/Jbc.M403141200 |
0.614 |
|
| 2004 |
Aschenbrenner L, Naccache SN, Hasson T. Uncoated endocytic vesicles require the unconventional myosin, Myo6, for rapid transport through actin barriers. Molecular Biology of the Cell. 15: 2253-63. PMID 15004223 DOI: 10.1091/Mbc.E04-01-0002 |
0.641 |
|
| 2003 |
Aschenbrenner L, Lee T, Hasson T. Myo6 facilitates the translocation of endocytic vesicles from cell peripheries. Molecular Biology of the Cell. 14: 2728-43. PMID 12857860 DOI: 10.1091/Mbc.E02-11-0767 |
0.627 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2006 |
Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents and Chemotherapy. 50: 1470-9. PMID 16569867 DOI: 10.1128/AAC.50.4.1470-1479.2006 |
0.166 |
|
| 2011 |
Larson JL, Kang SK, Choi BI, Hedlund M, Aschenbrenner LM, Cecil B, Machado G, Nieder M, Fang F. A safety evaluation of DAS181, a sialidase fusion protein, in rodents. Toxicological Sciences : An Official Journal of the Society of Toxicology. 122: 567-78. PMID 21572096 DOI: 10.1093/toxsci/kfr109 |
0.158 |
|
| 2011 |
Triana-Baltzer GB, Sanders RL, Hedlund M, Jensen KA, Aschenbrenner LM, Larson JL, Fang F. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. The Journal of Antimicrobial Chemotherapy. 66: 15-28. PMID 21097900 DOI: 10.1093/jac/dkq387 |
0.156 |
|
| 2016 |
Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho WH, Zhou D, Wu A, Kraynov E, Aschenbrenner L, Han B, O'Donnell CJ, Pons J, Rajpal A, et al. RN927C, a site-specific Trop-2 antibody-drug-conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Molecular Cancer Therapeutics. PMID 27582525 DOI: 10.1158/1535-7163.Mct-16-0431 |
0.155 |
|
| 2008 |
Nicholls JM, Aschenbrenner LM, Paulson JC, Campbell ER, Malakhov MP, Wurtman DF, Yu M, Fang F. Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. The Journal of Antimicrobial Chemotherapy. 62: 426-8; author reply . PMID 18434340 DOI: 10.1093/Jac/Dkn167 |
0.125 |
|
| 2019 |
Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, et al. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics. PMID 31434693 DOI: 10.1158/1535-7163.Mct-19-0007 |
0.121 |
|
| 2010 |
Triana-Baltzer GB, Babizki M, Chan MC, Wong AC, Aschenbrenner LM, Campbell ER, Li QX, Chan RW, Peiris JS, Nicholls JM, Fang F. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. The Journal of Antimicrobial Chemotherapy. 65: 275-84. PMID 19942616 DOI: 10.1093/jac/dkp421 |
0.116 |
|
| 2020 |
Reynolds VL, Butler P, Abernathy MM, Aschenbrenner L, Best DD, Blank J, Crosby M, Custer L, Escobar PA, Kolaja K, Moggs J, Shuey D, Snyder C, Van Vleet T, Zhou J, et al. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective. Regulatory Toxicology and Pharmacology : Rtp. 117: 104746. PMID 32911461 DOI: 10.1016/j.yrtph.2020.104746 |
0.086 |
|
| 2019 |
Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, et al. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Scientific Reports. 9: 8420. PMID 31182754 DOI: 10.1038/s41598-019-44874-0 |
0.08 |
|
| 2007 |
Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim DH, Malakhov MP, Yu M, Fang F, Katz JM. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. The Journal of Infectious Diseases. 196: 1493-9. PMID 18008229 DOI: 10.1086/522609 |
0.072 |
|
| 2010 |
Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. The Journal of Infectious Diseases. 201: 1007-15. PMID 20170378 DOI: 10.1086/651170 |
0.071 |
|
| 2022 |
Buetow BS, Cappon GD, Aschenbrenner LM, Updyke L, Torti VR, Evans M, Dalton SR, Bailey S, Bowman CJ. Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats. International Journal of Toxicology. 10915818221106397. PMID 35672934 DOI: 10.1177/10915818221106397 |
0.052 |
|
| 2019 |
Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, et al. Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Scientific Reports. 9: 16735. PMID 31700121 DOI: 10.1038/s41598-019-53130-4 |
0.044 |
|
| Hide low-probability matches. |